We live in an era when value is unprecedentedly created.
Big data, artificial intelligence, cloud computing, the Internet of Things... Emerging technologies are constantly emerging, and in many fields, many innovative “unicorn†companies have been created, which have created tremendous value for the society.
In 2018, the "unicorn" began to appear in the field of medical big data and AI.
Zero-Technology, which completed the D-round financing of China Investment this year, became the first unicorn enterprise in the domestic medical big data and AI track, perhaps indicating that the field is ushered in an outbreak. Exploring the logic of zero growth has a certain meaning for the industry.
Massive data VS is quite misdiagnosed
It is estimated that we add 4 million cancer patients every year, the treatment cost reaches 400 billion yuan, 40% of patients are misdiagnosed. The incidence and mortality of cancer are high, which seriously threatens the lives and health of the people and becomes a heavy burden on society.
Such a large number of tumor data from the clinical front line is undoubtedly extremely valuable for improving the accuracy of diagnosis and treatment - how to tap and further activate the value of data is an urgent problem to be solved, and it is also a strong need of the industry.
The initial heart of zero is here. It hopes to deepen the field of tumor big data, turn the sleeping cancer records of China into usable data, empower the medical and pharmaceutical industries, improve the quality and efficiency of scientific research and diagnosis, and reduce the cost of medicine.
In the United States, for example, there are 1.7 million cancer patients in the United States each year, and 3% of medical records are applied. This is also the basis for the development of most new cancer drugs in the world. It is conceivable that if the remaining 97% of the medical records are applied, the value produced will be unimaginable. The same is true for my country.
The tumor is just a cut-off "narrow point", and the zero-point is aimed at a vast and healthy industry that is looking forward to change. According to the "Health China 2030" Plan, by 2030, the total size of China's health service industry will reach 16 trillion, and the medical big data industry is at the pivotal position of the trillion industry, playing an important role in leading, driving and connecting. effect.
More than data, good use is the ability - care data to care life's industrial closed loop
Create a big data platform and connect to the information island of 700+ hospitals to achieve in-hospital information integration. Through the follow-up team, you can obtain high-quality scientific research data. In the data processing stage, Zero and the oncologists established a consistency model and terminology set, through the structured processing engine (DRESS), machine learning engine (Fellow-X), accurately structured data processing of medical records, achieving 95% The patient's medical records are stored in the second grade, and the big data analysis and mining, together with various frontier models and algorithms, build professional medical knowledge base data.
At this point, Zero has achieved "own data." Up to now, the disease data of 625,000+ pages have been processed on the next day, and the accumulated structured cases have reached 3.8 million+ cases. Based on this, the largest big data platform in China has been established, and the penetration rate of single tumors has reached 60%.
Zero does not stop here, continue to explore the data mining analysis stage, apply data visualization system, machine learning (AI), clustering and correlation prediction, RWE-Data business system, in-depth analysis and mining of data. On this basis, Zero æ°ª began to pursue the redemption of data values, and carried out patient management / hospital medical services, clinical medical services, and pharmaceutical industry services.
From data integration, data processing, to analysis and mining, value realization, the industry closed loop that truly forms care data to care life.
As a person in charge said, “Having data is not an end, data is not a product, data is just a raw material, and the ability to redeem data is more important.â€
In fact, including drug development and evaluation, pharmaceutical marketing and circulation, commercial health insurance, assisted diagnosis and adjuvant therapy, genetic data integration analysis, academic and scientific services, medical professional education, and even drug regulation, public health management, etc., in new Under the times, they all face the challenges of low efficiency, high cost and poor quality. The zero-big data solution is undoubtedly of great value and attractiveness.
Tripartite service layout pulls high system solution value
Zero-COO Dinglihua said in an interview with the media that for the moment, the value of zero-valued data is mainly focused on three levels: “serving hospitals, serving pharmaceutical companies, and serving patients.â€
At the hospital level, the use of medical big data capabilities to assist clinical research and clinical diagnosis and treatment of doctors. For example, at the ASCO conference in 2018, Zero spent only three months supporting 10 experts, using a big data queue to produce 10 world-class scientific research results, one of which won the big prize "Merit Award"; zero AI-pulmonary nodule intelligent diagnosis system, assisting doctors, improve the doctor's diagnostic accuracy by 60%-80%, and shorten the diagnosis time by 25%. At present, Zero is the first lung cancer AI auxiliary diagnosis and treatment platform in Tianjin and Beijing, and 350 real applications per day. In addition, Zero æ°ª also provides patients with follow-up services, using data analysis and processing capabilities to achieve long-term effective follow-up rate of more than 85%, the effective follow-up rate of enrolled patients in research projects is higher than 90%.
At the level of service pharmaceutical companies, Zero is using real-world research and data insight business to empower pharmaceutical companies. Previously, a drug manufacturer's thrombopoietin hopes to explore the relationship between the dose and the patient's body weight. Based on big data, we can analyze the true tumor burden distribution and explore the body weight distribution and thrombocytopenia by retrospective real-world research. The ratio, which tells the drug company whether it is necessary to open up the market. Zero also carries out recruitment services for participants, using big data to efficiently and accurately enroll all processes, and one party helps pharmaceutical companies to improve research and development efficiency, reduce research and development costs, and make new therapeutic drugs more clinically applicable; It also brought more beneficial and updated treatments to the subjects, thus improving the health of the patients and improving the quality of life of the subjects.
Whether it is serving a hospital or serving a pharmaceutical company, it will eventually need to reach the patient.
In 2017, Zero Dust began to deploy a new DTP pharmacy with big data empowerment - a neighboring wise pharmacy. As the entrance to the offline scene of the patient, the neighboring wise pharmacy can not only connect doctors and patients through the Internet hospital platform, but also accurately connect patients and pharmaceutical companies, connect hospitals, pharmaceutical companies and patients to achieve a closed-loop management process. On October 27 this year, the neighboring wise pharmacy completed the first injection of the PD-1 product, the Odivo patient, which marked the ability of the neighboring wise pharmacy to have a “DTP+ day clinicâ€. As of the end of December 2018, the layout of 40 stores has been completed. Recently, the neighboring wise pharmacy has won the "Arter Net · Future Medical Top 100 - DTP Pharmacy TOP5".
New medical ecology achieves ultimate medical value
In just four years, from possessing data to possessing capabilities, Zero is playing an increasingly important role in the center of the 16 trillion health industry. The left hand is the data capacity required for industrial development, and the right hand is vast. The market application, zero supply and demand, establish links, and ultimately drive the industry.
In this process, Zero is determined to become a new medical ecological hydropower coal, empowering each role in each new medical ecological chain, improving quality, efficiency, and cost reduction for each link, and finally, achieving “activation data†Smart, everyone can enjoy accurate medical services."
It can be seen that it is no accident that Zero is the first unicorn in the field of medical big data and AI.
In a recent industry forum, a senior media person commented on Zero, "Congratulations to Zero, not only because Zero has become a new unicorn, but that Zero has a unicorn that can become a bigger company. Thinking and strength."
In the phrase.
On June 19 this year, Han Zheng, member of the Standing Committee of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, visited the city and confirmed and encouraged the zero-death. It is necessary to continue to follow the road of independent innovation of China's medical big data enterprises.
As a medical unicorn and a unicorn on the AI ​​track, Zero 必然 will inevitably shoulder more “social responsibility†in the future, and at the same time, in the context of big data becoming a national strategic resource and artificial intelligence in the world, the country is in full swing.氪 is even more responsible for continuous innovation, driving industry and social progress.
Head Massage,Head Massage Spa,Best Head Massager,Relaxing Head Massage
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizons.com